Abstract
Health technology assessment (HTA) plays a crucial role in the reimbursement decision-making process in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. To harmonise methodological standards and foster collaboration among European HTA bodies, several joint HTA initiatives have been established. Our review aimed to provide a concise overview and comparison of joint HTA and drug price collaborations and to gain an understanding of how these impact pricing and market access.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
